Document ID: FDA-2008-N-0037-0001
Agency: fda
Document Type: Notice
Title: Psychopharmacologic Drugs Advisory Committee; Amendment of Notice
Posted Date: 2008-01-16T05:00Z

[Federal Register: January 16, 2008 (Volume 73, Number 11)]
[Notices]               
[Page 2924-2925]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr16ja08-63]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

 
Psychopharmacologic Drugs Advisory Committee; Amendment of Notice

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

    The Food and Drug Administration (FDA) is announcing an amendment 
to the notice of meeting of the Psychopharmacologic Drugs Advisory 
Committee. This meeting was announced in the Federal Register of 
December 19, 2007 (72 FR 71923). The amendment is being made to reflect 
changes in the Location, Contact Person, and Procedure portions of the 
document. There are no other changes.

FOR FURTHER INFORMATION CONTACT: Diem-Kieu Ngo, Center for Drug 
Evaluation and Research (HFD-21), Food and Drug Administration, 5600 
Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), 
Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail: 
diem.ngo@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-

800-741-8138 (301-443-0572 in the Washington DC area), code 3014512544. 
Please call the Information Line for up-to-date information on this 
meeting.

SUPPLEMENTARY INFORMATION: In the Federal Register of December 19, 
2007, FDA announced that a meeting of the Psychopharmacologic Drugs 
Advisory Committee would be held on February 6, 2008.
    On page 71923, in the third column, the Location portion of the 
document is changed to read as follows:
    Location: Crowne Plaza/Silver Spring, Kennedy Ballrooms, 8777 
Georgia Ave., Silver Spring, MD. The hotel telephone number is 301-589-
0800.
    On page 71923, in the third column, the first sentence of the 
Contact Person portion of the document is changed to read as follows:
    Contact Person: Diem-Kieu Ngo, Center for Drug Evaluation and 
Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, 
(for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 
20857, 301-827-7001, FAX: 301-827-6776, e-mail: diem.ngo@fda.hhs.gov, 
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), code 3014512544.
    On page 71924, in the first column, the first paragraph of the 
Procedure portion of the document is changed to read as follows:
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person on or before 
January 18, 2008. Oral presentations from the public will be scheduled 
between approximately 1:30 p.m. and 2:30 p.m. Those desiring to make 
formal oral presentations should notify the contact person and submit a 
brief statement of the general nature of the evidence or arguments they 
wish to present, the names and addresses of proposed participants, and 
an indication of the approximate time requested to make their 
presentation on or before January 10, 2008. Time allotted for each 
presentation may be limited. If the number of registrants requesting to 
speak is greater than can be reasonably accommodated during the 
scheduled open public hearing session, FDA may conduct a lottery to 
determine the speakers for the scheduled open public hearing session. 
The contact person will notify interested persons

[[Page 2925]]

regarding their request to speak by January 11, 2008.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

    Dated: January 10, 2008.
Randall W. Lutter,
Assistant Commissioner for Policy.
[FR Doc. E8-726 Filed 1-15-08; 8:45 am]

BILLING CODE 4160-01-S